Zai Lab (ZLAB) said Monday that the US Food and Drug Administration has granted fast-track designation to ZL-1310, the company's potential antibody-drug conjugate for the treatment of extensive-stage small cell lung cancer.
The drug, currently being evaluated in a phase 1 clinical trial already received an FDA orphan drug designation for small cell lung cancer, the company said.
Fast-track designation will mean more frequent engagements with the FDA and eligibility for accelerated approval and priority review, the company said.
Shares of the company were up more than 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.